Cyclacel Pharmaceuti (CYCC) Stock Price, Quote & News

Latest News on CYCC

Mar 24, 2025, 7:30 AM EDT - 9 days ago

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Feb 27, 2025, 1:38 PM EST - 4 weeks ago

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Jan 3, 2025, 9:01 AM EST - 3 months ago

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Dec 5, 2024, 4:05 PM EST - 4 months ago

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Nov 14, 2024, 4:15 PM EST - 4 months ago

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 13, 2024, 12:22 PM EST - 5 months ago

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 12, 2024, 4:45 PM EST - 5 months ago

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Oct 24, 2024, 9:15 AM EDT - 5 months ago

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Oct 23, 2024, 9:15 AM EDT - 5 months ago

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Oct 9, 2024, 9:15 AM EDT - 6 months ago

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Sep 25, 2024, 9:15 AM EDT - 6 months ago

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

Sep 4, 2024, 9:15 AM EDT - 7 months ago

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 9:15 AM EDT - 7 months ago

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

Aug 14, 2024, 8:18 PM EDT - 8 months ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 9:15 AM EDT - 8 months ago

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

Jun 26, 2024, 9:15 AM EDT - 10 months ago

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Jun 4, 2024, 8:00 AM EDT - 10 months ago

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

May 14, 2024, 8:08 PM EDT - 11 months ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript

May 8, 2024, 9:15 AM EDT - 11 months ago

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

May 2, 2024, 4:30 PM EDT - 11 months ago

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 1, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

Mar 19, 2024, 6:09 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 4:05 PM EDT - 1 year ago

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 13, 2024, 4:05 PM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

Mar 7, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Mar 6, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

Feb 20, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

Jan 30, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

Jan 8, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jan 2, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

Dec 22, 2023, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

Dec 18, 2023, 9:00 AM EST - 1 year ago

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Dec 12, 2023, 4:05 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Reverse Stock Split

Nov 30, 2023, 9:15 AM EST - 1 year ago

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

Nov 28, 2023, 5:15 PM EST - 1 year ago

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

Nov 13, 2023, 7:32 PM EST - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

Aug 3, 2023, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results

May 11, 2023, 7:59 PM EDT - 2 years ago

Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Earnings Call Transcript

May 11, 2023, 4:05 PM EDT - 2 years ago

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

May 4, 2023, 9:15 AM EDT - 2 years ago

Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results

May 3, 2023, 9:15 AM EDT - 2 years ago

Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit

Mar 7, 2023, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals to Participate in March Investor Conferences

Mar 6, 2023, 9:04 PM EST - 2 years ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2022 Earnings Call Transcript

Mar 6, 2023, 4:05 PM EST - 2 years ago

Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update

Feb 27, 2023, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results

Jan 30, 2023, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference

Jan 5, 2023, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023

Dec 15, 2022, 9:15 AM EST - 2 years ago

Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023

Market Cap	1.69M
Revenue (ttm)	420,000.00
Net Income (ttm)	-22.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5,371.43%
Debt to Equity Ratio	0.00

Volume	303,000
Avg Vol	347,948
Day's Range	N/A - N/A
Shares Out	6.29M
Stochastic %K	22%
Beta	0.15
Analysts	Strong Buy
Price Target	$1.00